• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

    17.96 +0.63 (+3.64%)
    Streaming Delayed Price Updated: 1:44 PM EST, Jan 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Zai Lab Limited - American Depositary Shares

    News headline image
    Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Zai Lab: Q1 Earnings Insights ↗
     
    Via Benzinga
    News headline image
    Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Earnings Preview For Zai Lab ↗
     
    Via Benzinga
    News headline image
    Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
    YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC 
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For May 9, 2023 ↗
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
    Via Benzinga
    News headline image
    Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For March 1, 2023 ↗
    Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
    Via Benzinga
    News headline image
    Zai Lab's Earnings: A Preview ↗
     
    Via Benzinga
    News headline image
    Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
    Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET 
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
    New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) 
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off ↗
    This company plans to be profitable soon, and its revenue is already spiking. 
    Via The Motley Fool
    News headline image
    Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years ↗
    Biotechs are capable of making huge gains in short periods, and they often do. 
    Via The Motley Fool
    News headline image
    Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken ↗
    Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts... 
    Via Benzinga
    News headline image
    2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗
    They're down, but they aren't yet out. 
    Via The Motley Fool
    News headline image
    Why Shares of MacroGenics Jumped Thursday ↗
    The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
    Via The Motley Fool
    News headline image
    2 Growth Stocks With Incredible Potential in the Next 5 Years ↗
    Neither is profitable, but both could be on the verge of massive booms in revenue. 
    Via The Motley Fool
    News headline image
    Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
    Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
    Via Benzinga
    News headline image
    Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday ↗
    U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    News headline image
    Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
    Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million... 
    Via Benzinga
    News headline image
    Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Zai Lab Announces Participation in March Investor Conferences
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    3 More Mid-Cap Biotechs The Street Sees Doubling
    According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
    Via MarketBeat
    News headline image
    Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗
    Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
    Via Benzinga
    News headline image
    Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
    Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET 
    From Zai Lab Limited
    Via GlobeNewswire
    News headline image
    Zai Lab Announces Participation in February Investor Conferences
    From Zai Lab Limited
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.